Verve Therapeutics Stock Piotroski F Score

VERV Stock  USD 5.78  0.47  8.85%   
This module uses fundamental data of Verve Therapeutics to approximate its Piotroski F score. Verve Therapeutics F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Verve Therapeutics. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Verve Therapeutics financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out Verve Therapeutics Altman Z Score, Verve Therapeutics Correlation, Verve Therapeutics Valuation, as well as analyze Verve Therapeutics Alpha and Beta and Verve Therapeutics Hype Analysis.
For more information on how to buy Verve Stock please use our How to Invest in Verve Therapeutics guide.
  
At this time, Verve Therapeutics' Net Debt To EBITDA is fairly stable compared to the past year. Debt To Equity is likely to climb to 0.02 in 2024, despite the fact that Net Debt is likely to grow to (124.7 M). At this time, Verve Therapeutics' Graham Net Net is fairly stable compared to the past year. Price Book Value Ratio is likely to climb to 1.57 in 2024, whereas Operating Cash Flow Per Share is likely to drop (2.45) in 2024.
At this time, it appears that Verve Therapeutics' Piotroski F Score is Healthy. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
5.0
Piotroski F Score - Healthy
Current Return On Assets

Negative

Focus
Change in Return on Assets

Decreased

Focus
Cash Flow Return on Assets

Negative

Focus
Current Quality of Earnings (accrual)

Improving

Focus
Asset Turnover Growth

Increase

Focus
Current Ratio Change

Decrease

Focus
Long Term Debt Over Assets Change

N/A

Focus
Change In Outstending Shares

Decrease

Focus
Change in Gross Margin

Increase

Focus

Verve Therapeutics Piotroski F Score Drivers

The critical factor to consider when applying the Piotroski F Score to Verve Therapeutics is to make sure Verve is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Verve Therapeutics' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Verve Therapeutics' financial numbers are properly reported.
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.01640.0156
Sufficiently Up
Slightly volatile
Total Current Liabilities23.1 M37 M
Way Down
Slightly volatile
Non Current Liabilities Total85.1 M116.2 M
Way Down
Slightly volatile
Total Assets421.5 M752.7 M
Way Down
Slightly volatile
Total Current Assets365.5 M637.9 M
Way Down
Slightly volatile

Verve Therapeutics F Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Verve Therapeutics' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Verve Therapeutics in a much-optimized way.

About Verve Therapeutics Piotroski F Score

F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.

Book Value Per Share

9.81

At this time, Verve Therapeutics' Book Value Per Share is fairly stable compared to the past year.

Verve Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Verve Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Verve Therapeutics' managers, analysts, and investors.
Environmental
Governance
Social

About Verve Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Verve Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Verve Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Verve Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Verve Stock Analysis

When running Verve Therapeutics' price analysis, check to measure Verve Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verve Therapeutics is operating at the current time. Most of Verve Therapeutics' value examination focuses on studying past and present price action to predict the probability of Verve Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Verve Therapeutics' price. Additionally, you may evaluate how the addition of Verve Therapeutics to your portfolios can decrease your overall portfolio volatility.